Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being ...
Researchers from Stanford University have reported that inhibiting the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) ...
Raqualia Pharma Inc.’s Fimecs Inc. subsidiary has agreed with Astellas Pharma Inc. to add two new targets under their ongoing ...
Inhibiting transient receptor potential melastatin 2 (TRPM2) may mitigate injury arising from ischemic stroke. Researchers at ...
Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan ...
Researchers at Dana Farber Cancer Institute Inc. and Stanford University have identified RAF proto-oncogene serine/threonine-protein kinase (RAF1; cRaf) inhibitors reported to be useful for the ...
Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular ...
Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic ...
Eli Lilly & Co. has synthesized relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, acute kidney disease ...
Vivace Therapeutics Inc. reported preclinical efficacy data of VT-3989, a TEAD inhibitor, in in vitro and in vivo models of aggressive meningioma. VT-3989 is in early clinical development for the ...
Researchers from the Medical School of Nanjing University hypothesized that in ulcerative colitis, the gut-resident macrophages may be compromised, leading to impaired integrity of the epithelial ...
M-3554 is an antibody-drug conjugate (ADC) targeting GD2; it has shown strong antitumor activity in neuroblastoma xenograft models and has been engineered to reduce anti-GD2 antibody-associated pain.